206 related articles for article (PubMed ID: 37967403)
1. Risk of Lymphoma in Inflammatory Bowel Disease.
Siegel CA
Gastroenterol Hepatol (N Y); 2009 Nov; 5(11):784-790. PubMed ID: 37967403
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
[TBL] [Abstract][Full Text] [Related]
4. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
[TBL] [Abstract][Full Text] [Related]
5. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
Abraham NS; Richardson P; Castillo D; Kane SV
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
[TBL] [Abstract][Full Text] [Related]
6. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
7. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
Erdoğan Ç; Yeşil B; Bacaksız F; Arı D; Gökbulut V; Yüksel M; Özderin Özin Y; Kayaçetin E
Turk J Gastroenterol; 2022 Oct; 33(10):831-837. PubMed ID: 35946879
[TBL] [Abstract][Full Text] [Related]
8. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
9. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all.
Melmed GY; Spiegel BM; Bressler B; Cheifetz AS; Devlin SM; Harrell LE; Irving PM; Jones J; Kaplan GG; Kozuch PL; Velayos FS; Baidoo L; Sparrow MP; Siegel CA
Clin Gastroenterol Hepatol; 2010 Aug; 8(8):655-9. PubMed ID: 20451665
[TBL] [Abstract][Full Text] [Related]
10. Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis.
Kobayashi T; Uda A; Udagawa E; Hibi T
J Crohns Colitis; 2020 Jun; 14(5):617-623. PubMed ID: 31867632
[TBL] [Abstract][Full Text] [Related]
11. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?
Jones JL; Loftus EV
Inflamm Bowel Dis; 2007 Oct; 13(10):1299-307. PubMed ID: 17600819
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate).
Sattler L; Hanauer SB; Malter L
Curr Gastroenterol Rep; 2021 Dec; 23(12):30. PubMed ID: 34913108
[TBL] [Abstract][Full Text] [Related]
13. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
14. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T
Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355
[TBL] [Abstract][Full Text] [Related]
15. Do inflammatory bowel disease therapies cause cancer?
Mason M; Siegel CA
Inflamm Bowel Dis; 2013 May; 19(6):1306-21. PubMed ID: 23470503
[TBL] [Abstract][Full Text] [Related]
16. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study.
Cleynen I; Boucher G; Jostins L; Schumm LP; Zeissig S; Ahmad T; Andersen V; Andrews JM; Annese V; Brand S; Brant SR; Cho JH; Daly MJ; Dubinsky M; Duerr RH; Ferguson LR; Franke A; Gearry RB; Goyette P; Hakonarson H; Halfvarson J; Hov JR; Huang H; Kennedy NA; Kupcinskas L; Lawrance IC; Lee JC; Satsangi J; Schreiber S; Théâtre E; van der Meulen-de Jong AE; Weersma RK; Wilson DC; ; Parkes M; Vermeire S; Rioux JD; Mansfield J; Silverberg MS; Radford-Smith G; McGovern DP; Barrett JC; Lees CW
Lancet; 2016 Jan; 387(10014):156-67. PubMed ID: 26490195
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease.
Torres J; Boyapati RK; Kennedy NA; Louis E; Colombel JF; Satsangi J
Gastroenterology; 2015 Dec; 149(7):1716-30. PubMed ID: 26381892
[TBL] [Abstract][Full Text] [Related]
18. Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis.
Hashash JG; Fadel CGA; Rimmani HH; Sharara AI
Ann Gastroenterol; 2021; 34(5):612-624. PubMed ID: 34475731
[TBL] [Abstract][Full Text] [Related]
19. Familial occurrence and inheritance studies in inflammatory bowel disease.
Binder V; Orholm M
Neth J Med; 1996 Feb; 48(2):53-6. PubMed ID: 8819799
[TBL] [Abstract][Full Text] [Related]
20. Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease.
Law CC; Bell C; Koh D; Bao Y; Jairath V; Narula N
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013256. PubMed ID: 33098570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
